| Identification | Back Directory | [Name]
TREHALOSE 6,6'-DIMYCOLATE | [CAS]
61512-20-7 | [Synonyms]
CORD FACTOR
Trehalose dimycolate
TREHALOSE 6,6'-DIMYCOLATE
6,6'-di-o-mycoloyl-α,α-trehalose
Cord factor from Mycobacterium bovis
TREHALOSE 6,6′-DIMYCOLATE;CORD FACTOR
6,6'-DI-O-MYCOLOYL-ALPHA,ALPHA-TREHALOSE
6,6μ-Di-O-mycoloyl-α,α-trehalose, Cord factor
trehalose 6,6'-dimycolate from*mycobacterium tube
Trehalose 6,6′-diMycolate froM MycobacteriuM bovis
TREHALOSE 6,6'-DIMYCOLATE FROM*MYCOBACTE RIUM TUBERC
trehalose 6,6'-dimycolate from mycobacterium tuberculosis
6,6′-Di-O-mycoloyl-α,α-trehalose from Mycobacterium bovis
Trehalose 6,6'-dimycolate [Cord Factor] Endotoxin-free (sterile) | [Molecular Formula]
C130H250O15.C2H6 | [MDL Number]
MFCD18643296 |
| Hazard Information | Back Directory | [Uses]
Trehalose 6,6'-dimycolate (Cord Factor) is trehalose 6,6'-dimycolate, a cell wall glycolipid of Mycobacterium tuberculosis, which can be used to simulate inflammation and granuloma induced by Mycobacterium tuberculosis (MTB) form. Trehalose 6,6′-dimycolate also protects Mycobacterium tuberculosis from macrophage-mediated killing, inhibits efficient antigen presentation, and reduces the development of protective T cell responses[1][2]. | [in vivo]
1. Induce inflammation and granuloma formation[1] Pathogenic mechanism
Trehalose 6,6’-dimycolate prevents calcium-mediated fusion of phagosomes and lysosomes, inhibits phagolysosome acidification, and thereby inhibits the killing effect of mouse macrophages on Mycobacterium tuberculosis, impairs the body's effective immune response, and induces the expression of matrix metalloproteinases.
Specific modeling method
Mice: C57BL/6 ? female ? 6-8 week-old (period: 7 days)
Administration: 0.5 or 1.25 mg/kg ? i.v., or i.p. first then i.v. ? once
Modeling success index Phenotypic observation ：Macrophages gather locally, the size and number of granulomas increase, inflammation intensifies, alveolar spaces decrease, there are small hemorrhages, and lymphocytes mainly infiltrate at the junction of granulomas and blood vessels.
| Animal Model: | Female C57BL/6 mice (6-8 weeks, 20 g)[1] | | Dosage: | 0.5, 1.25 mg/kg (10 μg, 25 μg per 20 g mice) | | Administration: | Intravenous injection (i.v.) once (0.5, 1.25 mg/kg), or received 0.5 mg/kg via Intraperitoneal injection (i.p.) followed by an i.v. after 7 days of 0.5 mg/kg | | Result: | Increased the lung weight index (LWI).
Local aggregation of macrophages was observed 7 days later at 0.5 mg/kg.
The size and number of granulomas increased, inflammation intensified, alveolar spaces decreased, small hemorrhagic petechiae appeared, and lymphocytes mainly infiltrated at the intersection of granulomas and blood vessels at 1.25 mg/kg.
In i.p.+i.v. model, the inflammatory response was more aggressive.
Induced vascular remodeling and collagen deposition.
|
| [References]
[1] Hwang SA, et al. Mycobacterial trehalose 6,6'-dimycolate induced vascular occlusion is accompanied by subendothelial inflammation. Tuberculosis (Edinb). 2019 May;116S:S118-S122. DOI:10.1016/j.tube.2019.04.019
[2] Welsh KJ, et al. Trehalose 6,6'-dimycolate--a coat to regulate tuberculosis immunopathogenesis. Tuberculosis (Edinb). 2013 Dec;93 Suppl:S3-9. DOI:10.1016/S1472-9792(13)70003-9 |
|
| Company Name: |
Wuhan Fortuna Chemical Co.,Ltd
|
| Telephone: |
+86-2759207851; +86-18007136271 |
| Website: |
https://www.chemicalbook.com/manufacturer/Wuhan%20Fortuna%20chemical/ |
|